VEGFA and renal cell carcinoma: More recent successes have been reported with targeted therapies for RCC, including multikinase inhibitors that block VEGF and mTOR signaling, although responses are short-lived and acquired resistance hampers their overall benefits [3], [4], [5], [6], [7], [8], [9].